First human test of ZL-1503 begins to uncover how the body handles it
NCT ID NCT07658482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called ZL-1503 in healthy volunteers. The goal is to understand how the drug moves through the body, how safe it is, and how well people tolerate it after a single injection under the skin or into a vein. The study involves 36 healthy adults aged 18 to 65 and will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZL-1503
- What this could lead to
- If successful, this study could provide key data to support further development of ZL-1503 for potential future use in patients.
- What could go wrong
- This is an early phase 1 trial in healthy volunteers, so results may not predict effects in patients. Side effects or lack of tolerability could halt development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ZaiLab Site 18001
Auckland, Auckland, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults